期刊文献+

转染微小RNA-126对肺腺癌A549细胞增殖的影响 被引量:3

Effects of microRNA-126 on proliferation of lung adenocarcinoma A549 cells
原文传递
导出
摘要 目的 观察体外转染微小RNA-126(miR-126)对人肺腺癌A549细胞增殖的影响.方法 人肺腺癌A549细胞株进行体外培养,分为3组:A组用单纯脂质体处理,B组用miR-126对照系列处理,C组用miR-126处理.实时定量聚合酶链反应(Real-time PCR)检测miR-126表达,Western blot检测血管内皮生长因子(VEGF)蛋白的表达,噻唑蓝(MTT)比色法检测A549细胞增殖.结果 转染人工合成的miR-126后的C组miR-126表达上调至(0.786±0.132),与A组(0.453±0.085)、B组(0.432±0.092)比较差异有统计学意义(P<0.01);C组细胞的VEGF表达下调至(0.312±0.075),与A组(0.633±0.172)、B组(0.597±0.095)比较差异有统计学意义(P<0.01);C组的细胞增殖被明显抑制,与对照组比较差异有统计学意义(P<0.05).结论 转染miR-126能够明显增加A549细胞内miR-126的表达,并下调VEGF蛋白表达,抑制肺腺癌A549细胞生长. Objective To explore the effect of microRNA-126 (miR-126) on the proliferation of lung adenocarcinoma A549 cells.Methods 549 cells in vitro were divided into 3 groups:group A treated only with liposomes,group B with miR-126 control,and group C with miR-126.The expression of miR-126 was detected by using Real-time quantitative polymerase chain reaction (Real-time PCR),and that of vascular endothelial growth factor (VEGF) protein by Western blotting,and methyl thiazol tetrazolium (MTr) assay was used to examine the growth of A549 cells.Results In group C,the expression level of miR-126 was increased to (0.786 ±0.132) as compared with group A (0.453 ±0.085) and group B (0.432 ±0.092) (P 〈0.01),and the VEGF protein expression was decreased to (0.312 ± 0.075) as compared with group A (0.633 ±0.172) and group B (0.597 ±0.095) (P 〈0.01).The growth of A549 cells in group C was inhibited significantly as compared with group A and group B (P 〈 0.05).Conclusion MiR-126 transfection can significantly increase its expression in A549 cells,decrease the expression of VEGF protein,and suppress the cells growth.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第2期341-343,共3页 Chinese Journal of Experimental Surgery
基金 广东省科技计划资助项目(2011B080701100)
关键词 微小RNA-126 血管内皮生长因子 增殖 肺腺癌 MicroRNA-126 Vascular endothelial growth factor Proliferation Lung adenocarcinoma
  • 相关文献

参考文献2

二级参考文献28

共引文献85

同被引文献23

  • 1Bartel DP. MicroRNAs: genomics,biogenesis,mechanism,and function[J]. Cell,2004,116(2) :281-297. 被引量:1
  • 2Li XM,Wang AM,Zhang J,et al. Down-regulation of miR-126 expres-sion in colorectal cancer and its clinical significance[ J]. Med Oncol,2011,28(4) :1054-1057. 被引量:1
  • 3Yang J, Lan H, Huang X, et al. MicroRNA-126 inhibits tumor cellgrowth and its expression level correlates with poor survival in non-small cell lung cancer patients[ J]. PLoS One ,2012,7(8) :(^42978. 被引量:1
  • 4Akagi I,Miyashita M,Ishibashi 0,et al. Relationship between alteredexpression levels of MIR21 ,MIR143,MIR145 ,and MIR205 and clini-copathologic features of esophageal squamous cell carcinoma[ J]. DisEsophagus,2011,24(7) :523-530. 被引量:1
  • 5White MF. IRS proteins and the common path to diabeles [ J ]. Am JPhysiol Endocrinol Metab,2002,283 (3 ) :E413-E422. 被引量:1
  • 6Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G; American Society of Clinical Ontology. American Society of Clinical Oneology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 2009, 27 (36) : 6251-6266. 被引量:1
  • 7D'Addario G, Felip E; ESMO Guidelines Working Group. Non- small-cell lung cancer: ESMO clinical recommendations for diag- nosis, treatment and follow-up. Ann Oneol, 2009, 20 ( Suppl4) : 68-70. 被引量:1
  • 8Sandier A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355 (24): 2542-2550. 被引量:1
  • 9Kurishima K, Ohara G, Kagohashi K, Takayashiki N, Tamura T, Shiozawa T, Miyazaki K, Kawaguchi M, Satoh H, Hizawa N. Ossification and increased bone mineral density with zoledronic acid in a patient with lung adenoearcinorca: a ease report. Exp T- her Med, 2014, 8 (4): 1267-1270. 被引量:1
  • 10Man Y, Can J, Jin S, Xu G, Pan B, Shang L, Che D, Yu Q, Yu Y. Newly identified biorcarkers for detecting circulating tumor cells in lung adenocarcinoma. Tohoku J Exp Med, 2014, 234 (1): 29-40. 被引量:1

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部